Key Highlights

  • Third-quarter G&A jumped to USD 37.4 million from USD 9.7 million as Mineralys Therapeutics (NASDAQ:MLYS) assembled a commercial team, with professional fees alone USD 15.4 million higher.
  • Net loss in the quarter came to USD 57.3 million, which is USD 0.64 a share, up from USD 36.9 million or USD 0.52 a share twelve months earlier.
  • The company ended September with USD 624.7 million across cash and investments, and the FDA's target date for lorundrostat falls on December 22, 2026.
  • Losses for the first nine months hit USD 337.7 million versus USD 122.4 million, largely reflecting the USD 200.0 million paid to Tanabe Pharma in June 2026.

Pre-Launch Hiring and Fees Nearly Quadruple G&A

A 10-Q filed on November 4, 2026 covers Mineralys Therapeutics (NASDAQ:MLYS) through the period ending September 30, 2026. G&A expense increased by USD 27.7 million, reaching USD 37.4 million, which management links to preparing for a launch, citing USD 15.4 million in higher professional fees and USD 11.4 million in added staff costs. R&D spending dropped USD 8.8 million, to USD 22.7 million, once the lorundrostat pivotal study ended in 2025. The company has no product revenue. Despite other income, net falling to USD 2.8 million, the net loss expanded by USD 20.4 million, to USD 57.3 million.

Lorundrostat Awaits an FDA Decision on December 22

Lorundrostat, which the company is advancing, is a by-mouth aldosterone synthase blocker aimed at hypertension that is either uncontrolled or resistant to treatment. A new drug application went in during December 2025; regulators accepted it, setting a target action date of December 22, 2026. According to the filing, an advisory committee meeting is not currently expected. In March 2026, a Phase 2 sleep apnea study missed on its primary endpoint, with no clinically meaningful gap versus placebo, though blood pressure dropped 11.1 mmHg on the drug compared with 1.0 mmHg on placebo. Leadership is confident cash covers the planned operating budget, launch included, for a minimum of twelve months.

Tanabe Buyout, Term Loan and Dilution Risks

The June 2, 2026 payment of USD 200.0 million to Tanabe ended lorundrostat royalties, yet up to USD 255.0 million in commercial milestones remains owed. Separately, USD 100.0 million has been taken from a senior secured Facility capped at USD 500.0 million; the USD 150.0 million Tranche B hinges on approval. Equity sales are a second source: a June offering brought in roughly USD 143.6 million net, and at-the-market issuance contributed USD 20.2 million across nine months. Downside scenarios include a negative regulatory outcome, earlier repayment demands should approval be missing by September 30, 2027, and additional dilution from new shares. Weighted shares rose to 89.0 million from 70.6 million.

Where Things Stand

Launch readiness spending explains the figure. Hiring and adviser fees ahead of a possible approval are behind the G&A climb to USD 37.4 million, and that spending helped push the quarterly loss to USD 57.3 million at Mineralys Therapeutics (NASDAQ:MLYS). Liquidity of USD 624.7 million looks solid, yet the Tanabe outlay, the loan and this year's equity raises show how heavily the launch draws on capital. The filing gives no market reaction. The next checkpoint is the December 22, 2026 FDA action date; once it passes, the Tranche B draw, launch timing and financing needs should come into focus.